Additional file 4: of Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Pharmacokinetics results. Supplemental results for pharmacokinetics analysis. Table S3: Summary of pharmacokinetic exposure of paclitaxel in cycle 1 (absence of T-DM1) and cycle 2 (presence of T-DM1). Table S4: Summary of pharmacokinetic exposure of T-DM1-related analytes (serum T-DM1, serum total trastuzumab and plasma DM1) in cycle 1 following q3w dosing. Table S5: Summary of pharmacokinetic exposure of T-DM1-related analytes (serum T-DM1, serum total trastuzumab and plasma DM1) in cycle 1 following qw dosing. Figure S1: Mean paclitaxel concentration time profiles at (A) a dose of 65Â mg/m2 and (B) a dose of 80Â mg/m2. (DOC 732 kb)